Tampere University Hospital
- Address
- lock Available on a paid plan
Neoplasms and Hematologic Malignancies
At Tampere University Hospital, a large share of clinical research focuses on cancer care, spanning solid tumors and blood cancers. Studies in breast cancer, renal cell carcinoma, melanoma, lung cancer, colon cancer, and bladder cancer are exploring new ways to improve survival, reduce recurrence, and strengthen treatment effectiveness.
- Testing new immunotherapy and targeted therapy approaches for advanced and metastatic cancers
- Evaluating treatment options for lymphoma, leukemia, and myelodysplastic syndrome
- Studying adjuvant and maintenance strategies to prevent cancer recurrence
This research also includes trials aimed at improving outcomes for patients with hormone receptor-positive breast cancer and other hard-to-treat tumors, reflecting a strong oncology program with broad clinical expertise.
Female Urogenital Diseases and Pregnancy Complications
The department is also studying conditions in women’s health, especially endometriosis and endometrial cancer. These trials look at symptom relief, fertility-related concerns, and better treatment after surgery for gynecologic cancer.
- Assessing therapies for endometriosis-associated pain and infertility
- Evaluating treatments for high-risk endometrial cancer
- Improving post-surgical care and disease control in gynecologic oncology
The work at Tampere University Hospital combines cancer research with practical questions that matter to patients, such as comfort, recovery, and long-term disease management.
Cardiovascular Diseases and Hemic and Lymphatic Diseases
Research in these areas includes studies on heart failure, atrial fibrillation, and stroke prevention, alongside trials in chronic lymphocytic leukemia and other blood disorders. The overall goal is to improve treatment effectiveness while balancing safety in complex patient groups.
- Testing new options for stroke prevention in patients with kidney disease and atrial fibrillation
- Evaluating therapies for heart failure and related cardiac dysfunction
- Studying better treatment strategies for chronic lymphocytic leukemia
These trials reflect a broad interest in both cardiovascular risk reduction and hematology, with attention to patients who often have multiple medical conditions.
Digestive System Diseases and Respiratory Tract Diseases
The site is investigating conditions such as ulcerative colitis, acute appendicitis, chronic obstructive pulmonary disease, and non-small cell lung cancer. This research aims to refine everyday treatment decisions and improve long-term disease control.
- Exploring better management of ulcerative colitis
- Studying whether antibiotics can be avoided in uncomplicated acute appendicitis
- Evaluating new approaches for COPD and lung-related disease burden
The clinical trial portfolio shows interest in both chronic inflammatory disease and respiratory illness, with a focus on practical treatment effectiveness and patient safety.
Male Urogenital Diseases and Environment and Public Health
Research also includes prostate cancer and public health-related questions that affect treatment quality and daily well-being. One example is work examining supportive care during cancer therapy, while other studies focus on reducing complications from common diseases.
- Studying supportive care for patients with prostate cancer
- Looking at ways to improve treatment tolerance and quality of life
- Addressing broader health outcomes linked to routine clinical care
Across these areas, the research at Tampere University Hospital reflects a patient-centered approach that combines disease treatment with attention to everyday health impacts.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 85 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1AstraZeneca AB3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tampere University Hospital
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2017-06-08 | 2025-03-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.